U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H13FN4O2
Molecular Weight 360.3412
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PD-169316

SMILES

[O-][N+](=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(F)C=C4

InChI

InChIKey=BGIYKDUASORTBB-UHFFFAOYSA-N
InChI=1S/C20H13FN4O2/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(8-4-15)25(26)27/h1-12H,(H,23,24)

HIDE SMILES / InChI

Molecular Formula C20H13FN4O2
Molecular Weight 360.3412
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22913737

PD-169316 is a selective inhibitor of p38 MAPK. It inhibits p38 MAPK with an IC50 of 89 nM. PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. In an amyloid β (Aβ) rat model of Alzheimer's disease it was demonstrated that caspase-3 and Bax/Bcl-2 ratio, two marks of apoptosis, were significantly decreased in the rats pre-treated with PD169316 intracerebroventricularly.This study suggested the potential neuroprotective role of PD 169316 against the neuronal toxicity induced by Aβ.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
89.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells.
2004 Mar
Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model.
2007 Jan
15-Deoxy-Delta-Prostaglandin J(2) Upregulates the Expression of LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats.
2009 Apr
Patents

Sample Use Guides

Rats: ICV infusion of PD169316 (30 ug/5ml 1% DMSO in PBS) with PBS injection (3 ul/side in CA1)
Route of Administration: Other
Pretreatment of CaOV3 cells with 10 uM PD-169316 resulted in decreased TGFb1-induced Smad2 and Smad3 phosphorylation
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:09:02 GMT 2023
Edited
by admin
on Sat Dec 16 08:09:02 GMT 2023
Record UNII
GX3Y2V80CV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PD-169316
Common Name English
PYRIDINE, 4-(4-(4-FLUOROPHENYL)-2-(4-NITROPHENYL)-1H-IMIDAZOL-5-YL)-
Systematic Name English
PYRIDINE, 4-(5-(4-FLUOROPHENYL)-2-(4-NITROPHENYL)-1H-IMIDAZOL-4-YL)-
Systematic Name English
J1.342.800J
Code English
2-(4-NITROPHENYL)-4-(4-FLUOROPHENYL)-5-(4-PYRIDINYL)-1H-IMIDAZOLE
Systematic Name English
PD168316
Code English
Code System Code Type Description
FDA UNII
GX3Y2V80CV
Created by admin on Sat Dec 16 08:09:02 GMT 2023 , Edited by admin on Sat Dec 16 08:09:02 GMT 2023
PRIMARY
PUBCHEM
4712
Created by admin on Sat Dec 16 08:09:02 GMT 2023 , Edited by admin on Sat Dec 16 08:09:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID8042684
Created by admin on Sat Dec 16 08:09:02 GMT 2023 , Edited by admin on Sat Dec 16 08:09:02 GMT 2023
PRIMARY
CAS
152121-53-4
Created by admin on Sat Dec 16 08:09:02 GMT 2023 , Edited by admin on Sat Dec 16 08:09:02 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR